Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 12, Issue 3, 2013, Pages 218-222

  Bendell, Johanna C ^a   Ervin, Thomas J ^b   Gallinson, David ^c   Singh, Jaswinder ^d   Wallace, James A ^e   Saleh, Mansoor N ^f   Vallone, Marcy ^a   Phan, See Chun ^g   Hack, Stephen P ^g  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b Florida Cancer Specialists   (United States)

^c Hematology Oncology Associates of Northern   (United States)

^d Midwest Cancer Care   (United States)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^f University of Alabama at Birmingham   (United States)

^g GENENTECH INC   (United States)

Author keywords

HGF MET pathway; Metastatic colorectal cancer; Onartuzumab; Vascular endothelial growth factor (VEGF)

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; METMAB; ONARTUZUMAB; OXALIPLATIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CANCER GROWTH; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; INTENTION TO TREAT ANALYSIS; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY (TOPIC); OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TIME TO TREATMENT; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR INVASION;

HGF/MET PATHWAY; METASTATIC COLORECTAL CANCER; ONARTUZUMAB; VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF);

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RESEARCH DESIGN; SURVIVAL RATE; YOUNG ADULT;

EID: 84883176380     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2013.04.001     Document Type: Article

References (15)

1. A. Jemal, R. Siegel, and J. Xu Cancer Statistics, 2010 CA: Cancer J Clin 60 2010 277 300
2. S. Kopetz, G.J. Chang, and M.J. Overman Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy J Clin Oncol 27 2009 3677 3683
3. G.P. Hess, P.F. Wang, and D. Quach Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice J Oncol Pract 6 2010 301 307
4. C. Birchmeier, W. Birchmeier, and E. Gherardi Met, metastasis, motility and more Nat Rev Mol Cell Biol 4 2003 915 925
5. M.F. Di Renzo Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer Clin Cancer Res 1 1995 147 154
6. S. Fujita, and K. Sugano Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases Jpn J Clin Oncol 27 1997 378 383
7. U.S. Kammula Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome Cancer Lett 248 2007 19 28
8. U. Stein, W. Walther, and F. Arlt MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis Nat Med 15 2009 59 67
9. R.A. Moss, J. Bothos, and P. Patel Developmental therapeutics Ann Oncol 21 2010 viii162 viii184
10. D.R. Spigel, T.J. Ervin, and R. Ramlau Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC J Clin Oncol 29 suppl 2011 abstract 7505. Available at: http://www.asco.org Accessed: June 3, 2013
11. J.M.L. Ebos, C.R. Lee, and W. Cruz-Munoz Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
12. M. Pàez-Ribes, E. Allen, and J. Hudock Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231
13. S. Pennacchietti Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene Cancer Cell 3 2003 347 361
14. D.P. Bottaro, and L.A. Liotta Cancer: out of air is not out of action Nature 423 2003 593 595
15. S. Kopetz, P.M. Hoff, and J.S. Morris Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance J Clin Oncol 28 2010 453 459